Payment overview · 2025
General Payments
$563.38
28 reported records · 11 companies
Healthcare provider profile · identity verified
David Michael Regalla, PAC
Physician Assistants & Advanced Practice Nursing Providers|Physician Assistant · GREENSBURG, PA · NPI 1982661468
Verified facts
What the public records show
CMS Open Payments records show David Michael Regalla, PAC received $563.38 in general payments during 2025 across 28 reported records.
MDD US Operations, LLC accounted for 20.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Nurtec Odt.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 92 claims for Nurtec Odt by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| MDD US Operations, LLC | Unresolved — no canonical attribution shown | $115.96 | 20.6% | 6 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $110.79 | 19.7% | 6 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $77.77 | 13.8% | 5 | 2025 |
| SK Life Science, Inc. |
SK Life Science, Inc. exact · evidence 2025-04-03 |
$68.08 | 12.1% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $60.54 | 10.8% | 3 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $28.27 | 5.0% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $25.35 | 4.5% | 1 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $21.36 | 3.8% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $20.30 | 3.6% | 1 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $18.04 | 3.2% | 1 | 2025 |
| Celgene Corporation | Unresolved — no canonical attribution shown | $16.92 | 3.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $563.38 | 28 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $110.79 | 6 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $77.77 | 5 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $77.77 | 5 | 2025 |
Source payment records
|
|||||
| KESIMPTA Normalized: kesimpta |
Drug | Novartis Pharmaceuticals Corporation | $60.54 | 3 | 2025 |
Source payment records
|
|||||
| Gocovri Normalized: gocovri |
Drug | MDD US Operations, LLC | $53.99 | 3 | 2025 |
Source payment records
|
|||||
| PONVORY Normalized: ponvory |
Drug | Vanda Pharmaceuticals Inc. | $28.27 | 1 | 2025 |
Source payment records
|
|||||
| AMYVID Normalized: amyvid |
Drug | Lilly USA, LLC | $25.35 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $25.35 | 1 | 2025 |
Source payment records
|
|||||
| Rystiggo Normalized: rystiggo |
Drug | UCB, Inc. | $21.36 | 1 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $20.30 | 1 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $18.04 | 1 | 2025 |
Source payment records
|
|||||
| ZEPOSIA Normalized: zeposia |
Drug | Celgene Corporation | $16.92 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 92 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
92 | 19 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 446 | 121 |
| Levetiracetam | Levetiracetam | 427 | 83 |
| Lamotrigine | Lamotrigine | 414 | 68 |
| Topiramate | Topiramate | 251 | 67 |
| Lacosamide | Lacosamide | 185 | 30 |
| Duloxetine Hcl | Duloxetine Hcl | 168 | 39 |
| Amitriptyline Hcl | Amitriptyline Hcl | 161 | 41 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 140 | 45 |
| Tizanidine Hcl | Tizanidine Hcl | 139 | 40 |
| Clonazepam | Clonazepam | 138 | 29 |
| Zonisamide | Zonisamide | 136 | 25 |
| Memantine Hcl | Memantine Hcl | 135 | 36 |
| Divalproex Sodium Er | Divalproex Sodium | 123 | 20 |
| Donepezil Hcl | Donepezil Hcl | 120 | 47 |
| Propranolol Hcl | Propranolol Hcl | 112 | 31 |
| Primidone | Primidone | 102 | 31 |
| Baclofen | Baclofen | 95 | 30 |
| Nurtec Odt | Rimegepant Sulfate | 92 | 19 |
| Aimovig Autoinjector | Erenumab-Aooe | 85 | 16 |
| Pregabalin | Pregabalin | 85 | 31 |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 84 | 34 |
| Carbamazepine Er | Carbamazepine | 82 | 18 |
| Emgality Pen | Galcanezumab-Gnlm | 80 | 16 |
| Rizatriptan | Rizatriptan Benzoate | 80 | 20 |
| Sumatriptan Succinate | Sumatriptan Succinate | 78 | 18 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 76 | 24 |
| Ubrelvy | Ubrogepant | 76 | 17 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 75 | 22 |
| Phenobarbital | Phenobarbital | 71 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 71 | 17 |
| Meloxicam | Meloxicam | 70 | 20 |
| Clopidogrel | Clopidogrel Bisulfate | 69 | 20 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 65 | 16 |
| Atorvastatin Calcium | Atorvastatin Calcium | 58 | 23 |
| Ropinirole Hcl | Ropinirole Hcl | 58 | 17 |
| Propranolol Hcl Er | Propranolol Hcl | 57 | 19 |
| Diazepam | Diazepam | 55 | 14 |
| Oxcarbazepine | Oxcarbazepine | 55 | 15 |
| Qulipta | Atogepant | 52 | 11 |
| Modafinil | Modafinil | 45 | suppressed |
| Dilantin | Phenytoin Sodium Extended | 43 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 43 | suppressed |
| Lorazepam | Lorazepam | 42 | 16 |
| Lamictal | Lamotrigine | 41 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 40 | 13 |
| Carbamazepine | Carbamazepine | 39 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 38 | suppressed |
| Entacapone | Entacapone | 36 | suppressed |
| Amantadine | Amantadine Hcl | 35 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 35 | suppressed |
| Alprazolam | Alprazolam | 26 | suppressed |
| Ethosuximide | Ethosuximide | 25 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 25 | suppressed |
| Risperidone | Risperidone | 25 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 25 | suppressed |
| Verapamil Er | Verapamil Hcl | 25 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 24 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 24 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 24 | suppressed |
| Aripiprazole | Aripiprazole | 23 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 23 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 23 | suppressed |
| Ibuprofen | Ibuprofen | 23 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 23 | suppressed |
| Dimethyl Fumarate | Dimethyl Fumarate | 22 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl | 22 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 22 | suppressed |
| Trihexyphenidyl Hcl | Trihexyphenidyl Hcl | 22 | 11 |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 21 | suppressed |
| Keppra | Levetiracetam | 21 | suppressed |
| Mirtazapine | Mirtazapine | 21 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 21 | suppressed |
| Dalfampridine Er | Dalfampridine | 20 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 19 | suppressed |
| Ondansetron Odt | Ondansetron | 19 | 13 |
| Celecoxib | Celecoxib | 18 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 18 | suppressed |
| Vimpat | Lacosamide | 18 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 17 | suppressed |
| Temazepam | Temazepam | 16 | suppressed |
| Zolmitriptan | Zolmitriptan | 15 | suppressed |
| Clobazam | Clobazam | 14 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 14 | suppressed |
| Aspirin-Dipyridamole Er | Aspirin/Dipyridamole | 13 | suppressed |
| Bupropion Xl | Bupropion Hcl | 13 | suppressed |
| Gamunex-C | Immune Globul G/Gly/Iga Avg 46 | 13 | suppressed |
| Lamotrigine Er | Lamotrigine | 13 | suppressed |
| Mysoline | Primidone | 13 | suppressed |
| Rasagiline Mesylate | Rasagiline Mesylate | 13 | suppressed |
| Rufinamide | Rufinamide | 13 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 13 | suppressed |
| Carisoprodol | Carisoprodol | 12 | suppressed |
| Droxidopa | Droxidopa | 12 | suppressed |
| Gammagard Liquid | Immun Glob G(Igg)/Gly/Iga Ov50 | 12 | suppressed |
| Lyrica | Pregabalin | 12 | suppressed |
| Neupro | Rotigotine | 12 | suppressed |
| Eszopiclone | Eszopiclone | 11 | suppressed |
| Omeprazole | Omeprazole | 11 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 11 | suppressed |
| Onfi | Clobazam | 11 | suppressed |
| Orphenadrine Citrate Er | Orphenadrine Citrate | 11 | suppressed |
| Privigen | Immun Glob G(Igg)/Pro/Iga 0-50 | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $563.38 · 28 records | MDD US Operations, LLC | AMYVID, Gocovri, INGREZZA, KESIMPTA, KISUNLA, Leqembi, NURTEC ODT, PONVORY, Rystiggo, VYEPTI, ZAVZPRET, ZEPOSIA | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Nurtec Odt play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with PFIZER INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error